In a letter to the World Health Organization dated December 13, India clarified that samples taken from Maiden Pharma, whose products were linked to the deaths of children in the Gambia, meet all the required specifications. In October, the Indian health authorities announced that the production of the cough and cold syrups at the Maiden Pharmaceuticals factory in Sonepat was halted after the global health agency reported that the drug might be linked to the deaths of 69 children in Gambia.

India′s drugs controller general, V.G. Somani, stated that tests on samples of Maiden Pharma′s products were found to be complying with specifications and showed the samples were not contaminated with ethylene glycol and diethylene glycol.

On Thursday, the Union Health Ministry released a copy of the letter to reporters. Additionally, the letter pointed out that the WHO′s statement in October, linking the deaths to the cough syrup manufactured in India, caused "irreparable damage" to the country′s supply chain of pharmaceutical products.

(Source: https://health.economictimes.indiatimes.com/news/pharma/india-says-samples-taken-from-pharma-firm-linked-to-gambia-deaths-meet-required-standards/96265046?utm_source=Mailer&utm_medium=newsletter&utm_campaign=ethealth_news_2022-12-16&dt=2022-12-16 )